6-O-methyl-α-D-glucose | 14199-58-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-O-methyl-α-D-glucose
• 英文别名: 6-O-Methyl-D-glucose；6-O-Methyl-α-D-glucopyranose；o-Methyl-beta-d-glucose；(2S,3R,4S,5S,6R)-6-(methoxymethyl)oxane-2,3,4,5-tetrol
• CAS: 14199-58-7
• 化学式: C₇H₁₄O₆
• 分子量: 194.185
• InChiKey: QWJKEQVWXSYDJA-ZFYZTMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-O-methyl-α-D-glucose 生成 6-O-methyl-β-D-glucose
  参考文献：
  名称：

  REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246

  摘要：

  DOI：
• 作为产物：
  描述：

  6-O-methyl-β-D-glucose 生成 6-O-methyl-α-D-glucose
  参考文献：
  名称：

  REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF ALDOSE REDUCTASE<br/>[FR] INHIBITEURS DE L'ALDOSE RÉDUCTASE
  申请人：APPLIED THERAPEUTICS INC

  公开号：WO2020205846A1

  公开（公告）日：2020-10-08

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

  本公开涉及新颖化合物及其药物组合物，以及促进皮肤健康老化、治疗皮肤疾病、心血管疾病、肾脏疾病、血管生成障碍（如癌症）、组织损伤治疗（如非心脏组织损伤）、心肌梗死演变治疗、缺血性损伤治疗以及利用本发明的化合物和组合物治疗糖尿病引起的并发症等方法。其他疾病可能包括但不限于动脉粥样硬化、心肌病、冠状动脉疾病、糖尿病肾病、糖尿病神经病变、糖尿病视网膜病变、糖尿病心肌病、皮肤感染、外周血管疾病、中风、半乳糖血症、哮喘、PMM2-CDG等。
• [EN] N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] N-(4-(AZAINDAZOL-6-YL)PHÉNYL)SULFONAMIDES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2014140065A1

  公开（公告）日：2014-09-18

  N-(4-(Azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及公式I的N-(4-(吡唑吲唑-6-基)-苯基)-磺酰胺，其中Ar、n、X、Z、R1、R2和R3具有索引中指示的含义。公式I的化合物是有价值的药理活性化合物，可以调节蛋白激酶活性，特别是血清和糖皮质激素调节激酶（SGK）的活性，特别是血清和糖皮质激素调节激酶同工酶1（SGK-1，SGK1）的活性，并适用于治疗SGK活性不当的疾病，例如退行性关节疾病或炎症过程，如骨关节炎或风湿病。本发明还涉及公式I的化合物的制备方法，它们作为药物的用途，以及包含它们的药物组合物。
• N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：US20160024097A1

  公开（公告）日：2016-01-28

  The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I中的N-(4-(氮杂吲唑-6-基)-苯基)-磺酰胺，其中Ar、n、X、Z、R1、R2和R3在权利要求中指定了它们的含义。式I化合物是有价值的药理活性化合物，可以调节蛋白激酶活性，特别是血清和糖皮质激素调节激酶（SGK）的活性，特别是血清和糖皮质激素调节激酶亚型1（SGK-1，SGK1）的活性，并适用于治疗SGK活性不当的疾病，例如退行性关节疾病或炎症过程，如骨关节炎或风湿病。此外，本发明还涉及制备式I化合物的方法，它们作为药物的用途以及包含它们的制剂。
• Talaromynoids A–E: Five New Fusicoccane Diterpenoids from the Endophytic Fungus <i>Talaromyces</i> sp. DC-26
  作者：Peng Zhou、Xiaotian Zhang、Chong Dai、Shan Yan、Mengsha Wei、Wenya Feng、Qin Li、Junjun Liu、Hucheng Zhu、Zhengxi Hu、Chunmei Chen、Yonghui Zhang

  DOI：10.1021/acs.joc.2c00528

  日期：2022.6.3

  Talaromynoids A–E (1–5), five new fusicoccane diterpenoids, were obtained from the endophytic fungus Talaromyces sp. DC-26, which was isolated from a wild leech. Talaromynoid A (1) represents the first fusicoccane diterpenoid bearing an unexpected 5–7–5 tricyclic ring system, which is possibly derived from normal 5–8–5 ones by ring contraction. Talaromynoid E (5) is characterized by an unusual oxygen

  从内生真菌Talaromyces sp.中获得五种新的 fusicoccane 二萜类化合物Talaromynoids A - E ( 1-5 )。DC-26，从野生水蛭中分离出来。Talaromynoid A ( 1 ) 代表第一个具有意想不到的 5-7-5 三环系统的 fusicoccane 二萜类化合物，它可能通过环收缩从正常的 5-8-5 三环系统衍生而来。Talaromynoid E ( 5 ) 的特点是在 C-1 和 C-8 之间有一个不寻常的氧桥，它使八元环 B 成为 9-氧代-双环[3.3.1]壬烷。1 - 5的结构通过广泛的 NMR 光谱分析、电子圆二色谱 (ECD) 计算、X 射线衍射分析和酸水解确定了绝对构型。
• REUBEN, JACQUES, CARBOHYDR. RES., 184,(1988) C. 244-246
  作者：REUBEN, JACQUES

  DOI：——

  日期：——